[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-161026064--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-161026064","PRESSRELEASE"," Aignostics Launches HETA Clinical, a New Family of AI Products that Speed Up Pathology Workflows and Reduce Failed Molecular Tests","2026-10-16T12:01:25.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> \nBERLIN and NEW YORK, Oct. 16, 2026 \u002FPRNewswire\u002F -- Today, Aignostics announced the launch of HETA \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.aignostics.com\u002Fclinical\u002Fheta-clinical\">Clinical,\u003C\u002Fa> a new family of pan-cancer AI products spanning the pathology workflow from intake and evaluation to molecular testing. The first four HETA Clinical products measure slide quality, tumor presence, mitotic counts and tumor cellularity across whole slide H&E images.\u003C\u002Fp>\u003Cp> - HETA Quality Control measures slide quality before analysis, identifying a range of slide quality issues.\u003C\u002Fp>\u003Cp> - HETA Tumor Detect annotates tumor regions and flags cases likely to contain tumor at scanning, so they are read first and additional stains can be ordered at intake.\u003C\u002Fp>\u003Cp> - HETA Mitosis counts mitoses, providing a reproducible mitotic count.\u003C\u002Fp>\u003Cp> - HETA Tumor Cellularity measures tumor cell content and proposes a region with sufficient tumor content to analyze with molecular testing.\u003C\u002Fp>\u003Cp> These assessments are usually made by eye, which is time-consuming, and visual estimates naturally vary from one reader to the next. Pathologists we spoke with at leading academic medical centers and precision medicine labs estimate that 10 to 20 percent of molecular tests fail because tissue lacks enough tumor, which can mean repeat biopsies and lengthy delays. HETA Clinical helps labs prioritize cases, cut turnaround time, and confirm samples have sufficient tumor prior to molecular testing.\u003C\u002Fp>\u003Cp> \"HETA Clinical gives labs a faster path through their workflow\" said Dr. Rosemarie \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Frosemarie-krupar\u002F\">Krupar,\u003C\u002Fa> VP of Pathology at Aignostics. \"Measurements like tumor content and mitotic count are central to many pathology specialties and shape much of the work that follows a slide. Quantifying them cell by cell is where AI delivers consistency at scale, freeing pathologists' time for the parts of the work that need their expertise.\"\u003C\u002Fp>\u003Cp> All four HETA Clinical products are based on HETA (formerly Atlas H&E-TME), Aignostics' core pan-cancer platform for spatial H&E tissue analysis. In a  [https:\u002F\u002Fwww.aignostics.com\u002Fblog\u002Fatlas-h-e-tme-scalable-ai-based-tissue-profiling-exceeds-expert-pathologist-level-performance]recent \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.aignostics.com\u002Fblog\u002Fatlas-h-e-tme-scalable-ai-based-tissue-profiling-exceeds-expert-pathologist-level-performance\">study,\u003C\u002Fa> cell classification by HETA matched or exceeded that of expert pathologists. Because HETA covers a broad range of cancer types, HETA Clinical brings AI to a wide range of pathology subspecialties, not only the most common cancer types.\u003C\u002Fp>\u003Cp> Aignostics also recently announced early access to \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.aignostics.com\u002Fclinical\u002Fpathosearch\">PathoSearch,\u003C\u002Fa> a visual search engine for pathology cases. More HETA Clinical products will be released over time and integrated with image management systems, including Techcyte Fusion® AP. Pathologists using Fusion can reach out to their Techcyte contact for a demo.\u003C\u002Fp>\u003Cp> Request a demo of HETA Clinical \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.aignostics.com\u002Fclinical\u002Fheta-clinical#heta-clinical-inquiries\">here.\u003C\u002Fa>\u003C\u002Fp>\u003Cp> For Research Use Only. Not for use in diagnostic procedures.\u003C\u002Fp>\u003Cp> About Aignostics\u003C\u002Fp>\u003Cp> Aignostics is an artificial intelligence company that delivers AI-powered tissue analyses, validated by pathologists. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine, supporting both biopharma R&D and clinical pathology labs. Established in 2020, Aignostics is a spin-off from Charité Berlin, one of the world's largest and most esteemed university hospitals. Aignostics is funded by leading investors such as Mayo Clinic and has operations in Berlin and New York.\u003C\u002Fp>\u003Cp> More information at: \u003Ca target=\"_blank\" href=\"http:\u002F\u002Fwww.aignostics.com\u002F\">www.aignostics.com\u003C\u002Fa>\u003C\u002Fp>\u003Cp> Follow us on LinkedIn: \u003Ca target=\"_blank\" href=\"http:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Faignostics\">www.linkedin.com\u002Fcompany\u002Faignostics\u003C\u002Fa>\u003C\u002Fp>\u003Cp> For media inquiries, please contact:\u003C\u002Fp>\u003Cp> Lisa Zheng, \u003Ca target=\"_blank\" href=\"mailto:lisa.zheng@aignostics.com\">lisa.zheng@aignostics.com\u003C\u002Fa>\u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp>  View original content to download multimedia:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Faignostics-launches-heta-clinical-a-new-family-of-ai-products-that-speed-up-pathology-workflows-and-reduce-failed-molecular-tests-302910720.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","BERLIN and NEW YORK, Oct. 16, 2026 \u002FPRNewswire\u002F -- Today, Aignostics announced the launch of HETA Clinical, a new family of pan-cancer AI products spanning the ",[16,21,26,31,36,41,46,51,56,61],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-161026176"," Paris Court Ruling on Discontinued Feature Will Have Minimal Impact on Angelalign Customers","2026-10-16T19:01:26.000+02:00","Angelalign Has Already Replaced Torque Ridges with Upgraded \"Pressure Points\" in Europe SAN CLEMENTE, Calif., Oct. 16, 2026 \u002FPRNewswire\u002F -- Angelalign Technolog",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-161026164"," Brazilian Fernanda Maciel Sets Salar de Uyuni Fastest Known Time of 19:50:08","2026-10-16T17:47:25.000+02:00","Red Bull athlete Fernanda Maciel (Brazil) crossed 172.8 kilometres of Bolivia's Salar de Uyuni, the world's largest salt flat, more than 13 hours faster than th",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-161026127"," Lenire Now Included in U.S. ENT Clinical Practice Guidelines - First New Treatment Added by American Academy of Otolaryngology Since Establishmen","2026-10-16T15:39:25.000+02:00","- The American Academy of Otolaryngology – Head and Neck Surgery Foundation has included Lenire (bimodal neuromodulation) as a treatment option for the first ti",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-161026121"," CLASSIC FUSION TRIBUTO: A GOLDEN RETURN TO THE 1980 ORIGIN","2026-10-16T15:32:25.000+02:00","MILAN, Italy, Oct. 16, 2026 \u002FPRNewswire\u002F -- Forty-six years later, Hublot pays tribute to the watch that built Hublot with the Classic Fusion Tributo in yellow ",{"id":37,"title":38,"pubDate":39,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-161026105"," Panzani and Cerealis Join Forces to Create a Major European Food Group","2026-10-16T15:01:25.000+02:00","The transaction would bring together two established European food manufacturers generating €1 billion in combined annual revenues, backed by Cerealis' founding",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-161026100"," Vale Base Metals completes transaction to establish new ownership of Thompson Mine Complex","2026-10-16T14:47:24.000+02:00","Transaction marks new chapter for Thompson, backed by US$200 million (approximately CAD$280 million) in new investment VBM retains 18.9% minority interest and m",{"id":47,"title":48,"pubDate":49,"logoUrl":8,"thirdParty":11,"orgId":13,"description":50},"CSN-161026088"," Huanyu Entertainment Showcases New Productions at 42nd MIPCOM Cannes","2026-10-16T13:37:25.000+02:00","AI Takes Center Stage as Huanyu Expands Its Global Reach CANNES, France, Oct. 16, 2026 \u002FPRNewswire\u002F -- The 42nd MIPCOM Cannes opened October 12 at the Palais de",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-161026085"," BOC Group Introduces ADOIT 21: Enterprise Architecture Within Reach of Every Stakeholder","2026-10-16T13:30:25.000+02:00","New capabilities make answers easier to find, put role-specific insights into focus, and connect applications with the processes they support. DUBLIN, Oct. 16, ",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-161026066"," oneworld, All 15 Members, Commit to Buckingham Palace Declaration","2026-10-16T12:03:25.000+02:00","Every member airline united in support of global initiative to prevent illegal wildlife trafficking BRUSSELS, Oct. 16, 2026 \u002FPRNewswire\u002F -- oneworld® and its 15",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14}]